HIV Diagnostics Market: Growth, Size, Share, and Trends

Report Code MD 5067
Published in Feb, 2025, By MarketsandMarkets™
Download PDF

Choose License Type

Buy Report Now Inquire Before Buying

HIV Diagnostics Market by Product (Assay Kits & Reagents, Instrument, Software), Test Type (Rapid Test, ELISA, Western Blot, Viral Load, CD4 Test), End User (Diagnostic Laboratories, Homecare Settings, Hospital) - Global Forecast to 2030

Overview

The global HIV diagnostics market, valued at US$2.96 billion in 2024, is forecasted to grow at a robust CAGR of 10.3%, reaching US$3.25 billion in 2025 and an impressive US$5.31 billion by 2030. The HIV diagnostics market is driven by several key factors, such as the rising prevalence of HIV/AIDS, the increasing number of blood transfusions and blood donations, advantages offered by POC diagnostic kits & instruments, and the growing focus on initiatives for HIV awareness. However, the high cost of nucleic acid testing, operational barriers, and the shortage of skilled laboratory technicians are expected to restrain the market growth to a certain extent.

Efforts driven by government health initiatives and public awareness campaigns promoting HIV testing are significantly boosting market growth. Additionally, innovations in testing technologies, such as rapid tests and self-testing kits, along with improved accuracy and ease of use, are enhancing patient compliance and encouraging wider adoption. Despite these positive developments, challenges like the high cost of diagnostic tests and complex testing procedures may slow down growth. However, the market is expected to continue progressing steadily, fueled by a stronger emphasis on early detection, improved healthcare access, and the increasing availability of advanced, convenient testing solutions.

HIV Diagnostics Market– Global Forecast and Key Opportunities to 2030

Attractive Opportunities in the HIV Diagnostics Market

Asia Pacific

The high growth rate of the Asia Pacific market is attributed to the expanding target patient population; improvements in healthcare infrastructure; rising incidence of HIV/AIDS; and favorable government initiatives on HIV screening & testing.

The market is driven by the large pool of HIV/AIDS patients, growing awareness of HIV, and increasing number of blood transfusion & blood donations worldwide.

The growing demand for home testing kits and emerging markets are expected to offer lucrative growth opportunities for market players.

The HIV diagnostics market in North America projected to reach USD 2,228.61 million by 2030, growing at a CAGR of 11.6% during the forecast period.

Product launches and partnerships were the most widely adopted growth strategies by market players.

Global HIV Diagnostics Market Dynamics

DRIVER: Growing prevalence of HIV/AIDS

The global prevalence of HIV/AIDS is a significant growth driver for the HIV/AIDS market. With the highest burden of HIV cases in regions such as Sub-Saharan Africa, the demand for accurate, accessible, and efficient diagnostic tools is critical. The ongoing challenge of diagnosing and treating individuals, combined with the rising number of new infections, highlights the growing need for innovative HIV diagnostics.

According to the World Health Organization (WHO), at the end of 2023, an estimated 39.9 million people were living with HIV, and approximately 1.3 million people acquired HIV during the same year. Therefore, as the prevalence and incidence of HIV/AIDS are on the rise, the demand for effective diagnostic solutions is also expected to contribute to market growth. The increasing number of new infections and the growing focus on early disease detection & diagnosis are expected to improve treatment outcomes, further emphasizing the importance of reliable HIV testing.

RESTRAINT: High cost of NATs

Nucleic Acid Testing (NAT) is a highly sensitive technique used in HIV diagnostics to detect the virus's genetic material (RNA or DNA) rather than antibodies or antigens, enabling early detection while monitoring the HIV prognosis. It plays a crucial role in blood screening, ensuring transfusion safety by identifying infected donations before antibodies develop. Nucleic acid tests (NATs) are relatively more expensive than ELISA tests as the cost of NAT instruments is higher regarding outright purchases and rental agreements. NAT instruments require heavy investments, which most blood banks cannot afford.

In addition to high instrument costs, NAT's operating expenses are also high. NAT testing involves a wide range of instruments that require separate infrastructure and a trained workforce. Small blood banks and those operated by charitable trusts & hospitals cannot afford these expenses. For instance, the ELISA test costs ~USD 3, whereas NAT tests are priced in the range of USD 15−120, as per a study conducted by the National AIDS Control Organization. An automated NAT machine costs ~INR 30 million in India. Also, in other countries, the overall price of NAT testing is around 20−30 USD, while ELISA tests cost around 10-15USD. Such price differentiations are expected to create a divide and limit the uptake of NAT tests for HIV detection.

As a result, several end users opt for rapid/ELISA testing in HIV diagnostics, which restricts the growth of the HIV diagnostics market to a certain extent during the forecast period.

 

OPPORTUNITY: Opportunities for growth in developing economies

Emerging economies exhibit substantial growth potential in the HIV diagnostics market, driven by factors such as high HIV prevalence, unsafe sexual practices, and limited awareness. For instance, in Sub-Saharan Africa, the prevalence of unprotected sex among college and university students is approximately 53%, contributing to higher transmission rates. Additionally, substance use, including alcohol consumption, has been linked to risky sexual behaviors, further exacerbating the spread of HIV. These behaviors are often compounded by a lack of awareness and education regarding HIV prevention and safe sex practices. Consequently, there is a pressing need for enhanced diagnostic services in these regions.

Also, the expansion of blood banks in emerging economies is poised to enhance HIV testing efforts significantly. Blood banks play a crucial role in ensuring safe blood supplies, which necessitates rigorous screening for HIV and other infectious agents. As the number of blood banks increases, so does the capacity for widespread HIV testing, contributing to early detection and prevention of transmission.

Global HIV Diagnostics Market Ecosystem Analysis

The HIV diagnostics market thrives on a complex ecosystem that interconnects various elements. It includes snoring consumables, instruments and siftware & services. Manufacturers focus on the design and optimization of tests. Distributors service these markets and include third-party vendors and e-commerce platforms. The key stakeholders include the diagnosed high-risk populations, investors, and regulatory bodies.

HIV Diagnostics Market
 

The consumables segment accounted for the largest share of the market in 2024, by product.

The HIV diagnostics market is segmented by product type into consumables, instruments, and software & services. In 2024, the consumables segment held the largest market share, primarily driven by sustained demand from diagnostic laboratories and healthcare facilities, the increasing prevalence of HIV/AIDS, and government initiatives aimed at advancing consumable technologies for HIV detection and monitoring.

Diagnostic Laboratories segment dominated the HIV diagnostics market in 2024, based on end user.

The HIV diagnostics market is categorized by end-user into diagnostic laboratories, hospitals, blood banks, home care settings, and other healthcare providers. In 2024, the diagnostic laboratories segment held the largest market share, primarily driven by the rising global prevalence of HIV/AIDS, the increasing establishment of specialized diagnostic facilities, a growing volume of HIV sample testing, and continuous advancements in point-of-care (POC) diagnostic instruments.

In 2024, North America held the largest share of the HIV diagnostics market.

The market for HIV diagnostics has been segmented into six major regions: North America, Europe, Asia Pacific, Latin America, the Middle East & Africa, and GCC Countries. North America was at the forefront in 2024. This growth is driven by the the increasing prevalence of HIV/AIDS, continuous advancements in point-of-care (POC) diagnostic instruments and test kits, growing awareness regarding HIV prevention and early detection, and the rising demand for blood transfusions and blood donations. The presence of well-established healthcare infrastructure, strong government initiatives supporting HIV screening programs, and significant investments in research and development further contribute to the region’s market leadership.

HIGHEST CAGR MARKET IN 2024
NORTH AMERICA FASTEST GROWING MARKET IN THE REGION
HIV Diagnostics Market

Recent Developments of HIV Diagnostics Market

  • In December 2024, Abbott signed an agreement with Siemens Healthineers AG (Germany), its Nigerian partner Tanit Medical Engineering, and Abbott Laboratories GmbH to enhance healthcare access in Nigeria.
  • In May 2023, Siemens Healthineers AG (Germany) launched two new analyzers: Atellica HEMA 570 Analyzer1 and the Atellica HEMA 580 Analyzer for hematology testing.

Key Market Players

KEY PLAYERS IN THE HIV DIAGNOSTICS MARKET INCLUDE

Want to explore hidden markets that can drive new revenue in HIV Diagnostics Market?

Scope of the Report

Report Metric Details
Market size available for years 2022-2030
Base Year Considered 2024
Forecast period 2025-2030
Forecast units Value (USD)
Segments covered product, test type, end user, and region
Geographies covered North America, Europe, Asia Pacific, Latin America, the Middle East & Africa and GCC Countries

 

Key Questions Addressed by the Report

What are the recent trends affecting the HIV diagnostics market?
Recent trends include the increasing prevalence of HIV/AIDS, benefits of point-of-care instruments and kits, and rising initiatives for HIV awareness. Challenges such as the high cost of NATs, operational difficulties, and a shortage of skilled laboratory technicians hinder market expansion. However, strong growth potential in emerging economies and the rising trend of self-testing present lucrative opportunities.
What are the major test types of HIV diagnostics?
The HIV diagnostics market is segmented into screening tests, confirmatory tests, and monitoring tests. The monitoring tests segment accounted for the largest share in 2024 and is expected to grow at the highest CAGR due to increasing awareness, high sample volume, establishment of diagnostic labs, and technological advancements in testing kits.
Who are the key players in the HIV diagnostics market?
Key players include Abbott (US), Siemens Healthineers AG (Germany), Thermo Fisher Scientific Inc. (US), Danaher Corporation (US), Grifols, S.A. (Spain), Bio-Rad Laboratories (US), F. Hoffmann-La Roche Ltd. (Switzerland), bioMérieux SA (France), Hologic, Inc. (US), QIAGEN (Germany), Becton, Dickinson, and Company (US), Trinity Biotech (Ireland), OraSure Technologies (US), BioSynex SA (France), Wondfo (China), Getein Biotech Inc. (China), Meril Diagnostics (India), AccuBioTech (China), BioLytical Laboratories Inc. (Canada), BioLab Diagnostics (India), Alpine Biomedicals Pvt. Ltd. (India), Molbio Diagnostics (India), Fortress Diagnostics (UK), AdvaCare Pharma (US), Adaltis s.r.l (Italy), among others.
What are the major distribution channels of HIV diagnostics?
The market includes diagnostic laboratories, hospitals, blood banks, home care settings, and other end users. The diagnostic laboratories segment held the largest market share in 2024 due to the increasing prevalence of HIV/AIDS, rising establishment of diagnostic labs, growing sample testing, and advancements in PoC instruments.
Which region is lucrative for the HIV diagnostics market?
The Asia-Pacific region is highly promising due to the rising target patient population, expansion of emerging economies, increasing availability of technologically advanced POC products, favorable government initiatives for HIV awareness, and the expansion of global players in this region.

 

Personalize This Research

  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
Request A Free Customisation

Let Us Help You

  • What are the Known and Unknown Adjacencies Impacting the HIV Diagnostics Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
Customized Workshop Request

Table Of Contents

Exclusive indicates content/data unique to MarketsandMarkets and not available with any competitors.

TITLE
PAGE NO
INTRODUCTION
27
RESEARCH METHODOLOGY
32
EXECUTIVE SUMMARY
44
PREMIUM INSIGHTS
47
MARKET OVERVIEW
51
  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    DRIVERS
    - Rising prevalence of HIV/AIDS
    - Increasing number of blood transfusions & blood donations
    - Advantages offered by POC diagnostic kits & instruments
    - Increasing initiatives for HIV awareness campaigns
    RESTRAINTS
    - High cost of NATs
    OPPORTUNITIES
    - High growth potential of emerging economies
    - Trend of self-testing and growing preference for at-home diagnostic kits
    CHALLENGES
    - Operational barriers and shortage of skilled laboratory technicians
  • 5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
  • 5.4 PRICING ANALYSIS
    AVERAGE SELLING PRICE OF HIV DIAGNOSTIC PRODUCTS, BY KEY PLAYER, 2023
    AVERAGE SELLING PRICE TREND, BY TEST TYPE, 2021−2023
    AVERAGE SELLING PRICE TREND OF HIV DIAGNOSTIC INSTRUMENTS, BY REGION, 2021−2023 (USD)
  • 5.5 VALUE CHAIN ANALYSIS
  • 5.6 SUPPLY CHAIN ANALYSIS
  • 5.7 ECOSYSTEM ANALYSIS
  • 5.8 TECHNOLOGY ANALYSIS
    KEY TECHNOLOGIES
    - ELISA
    COMPLEMENTARY TECHNOLOGIES
    - Western blot tests
    ADJACENT TECHNOLOGIES
    - PCR
  • 5.9 INVESTMENT & FUNDING SCENARIO
  • 5.10 PATENT ANALYSIS
  • 5.11 TRADE ANALYSIS
    IMPORT DATA FOR HS CODE 3822
    EXPORT DATA FOR HS CODE 3822
  • 5.12 KEY CONFERENCES & EVENTS, 2025–2026
  • 5.13 CASE STUDY ANALYSIS
    ROLE OF COMMUNITY-BASED ORGANIZATIONS (CBOS) IN SUPPORTING PEOPLE WITH HIV
    MANAGING HIGH BLOOD PRESSURE AND BLOOD SUGAR IN HIV-POSITIVE PATIENTS
  • 5.14 REGULATORY LANDSCAPE
    REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    REGULATORY FRAMEWORK
    - North America
    - Europe
    - Asia Pacific
    - Latin America
    - Middle East
    - Africa
  • 5.15 PORTER’S FIVE FORCES ANALYSIS
    THREAT OF NEW ENTRANTS
    THREAT OF SUBSTITUTES
    BARGAINING POWER OF BUYERS
    BARGAINING POWER OF SUPPLIERS
    INTENSITY OF COMPETITIVE RIVALRY
  • 5.16 KEY STAKEHOLDERS & BUYING CRITERIA
    KEY STAKEHOLDERS IN BUYING PROCESS
    KEY BUYING CRITERIA, BY PRODUCT
  • 5.17 IMPACT OF AI/GENERATIVE AI ON HIV DIAGNOSTICS MARKET
    MARKET POTENTIAL OF AI IN HIV DIAGNOSTICS
    AI USE CASES
    COMPANY IMPLEMENTATION OF AI
    FUTURE OF AI/GENERATIVE AI
HIV DIAGNOSTICS MARKET, BY TEST TYPE
84
  • 6.1 INTRODUCTION
  • 6.2 SCREENING TESTS
    RAPID TESTS
    - Provision of quick test results and ability to diagnose HIV antibodies to fuel uptake
    ELISA
    - Wide applications across infectious disease diagnostics to drive market
    OTHER SCREENING TESTS
  • 6.3 CONFIRMATORY TESTS
    WESTERN BLOT TESTS
    - Gold standard testing for result validation to drive market
    OTHER CONFIRMATORY TESTS
  • 6.4 MONITORING TESTS
    VIRAL LOAD TESTS
    - Accurate provision of quantitative data on HIV infections to boost demand
    CD4 TESTS
    - Ability to number CD4 T lymphocyte cells to support market growth
  • 6.5 OTHER HIV DIAGNOSTIC TESTS
HIV DIAGNOSTICS MARKET, BY PRODUCT
110
  • 7.1 INTRODUCTION
    CONSUMABLES
    ASSAY KITS & REAGENTS
    - Recurrent purchase to fuel market
    OTHER CONSUMABLES
  • 7.2 INSTRUMENTS
    RISING TECHNOLOGICAL ADVANCEMENTS TO DRIVE MARKET
  • 7.3 SOFTWARE & SERVICES
    INCREASING DEMAND FOR VALUE-ADDED SERVICES & AUTOMATED SOFTWARE TO SUPPORT MARKET GROWTH
HIV DIAGNOSTICS MARKET, BY END USER
125
  • 8.1 INTRODUCTION
  • 8.2 DIAGNOSTIC LABORATORIES
    HIGH VOLUME OF HIV TESTING SAMPLES TO PROPEL MARKET
  • 8.3 HOSPITALS
    INCREASING ADOPTION OF DIAGNOSTIC TOOLS AND FAVORABLE REIMBURSEMENTS TO DRIVE MARKET
  • 8.4 BLOOD BANKS
    RISING NUMBER OF BLOOD DONATIONS TO BOOST DEMAND
  • 8.5 HOME CARE SETTINGS
    INCREASING PREFERENCE FOR AT-HOME TESTING KITS TO SUPPORT MARKET GROWTH
  • 8.6 OTHER END USERS
HIV DIAGNOSTICS MARKET, BY REGION
138
  • 9.1 INTRODUCTION
  • 9.2 NORTH AMERICA
    MACROECONOMIC OUTLOOK FOR NORTH AMERICA
    US
    - High healthcare expenditure to drive market
    CANADA
    - Increasing number of HIV infections and blood donations to drive market
  • 9.3 EUROPE
    MACROECONOMIC OUTLOOK FOR EUROPE
    GERMANY
    - Favorable government healthcare policies and reimbursements for HIV testing to drive market
    UK
    - Rising government support for HIV awareness campaigns to support market growth
    FRANCE
    - High prevalence of HIV/AIDS to boost demand
    ITALY
    - Increasing number of blood donors to support market growth
    SPAIN
    - Rising adoption of NAT technology to propel market
    REST OF EUROPE
  • 9.4 ASIA PACIFIC
    MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
    CHINA
    - Rising incidence of infectious diseases & HIV to propel market
    JAPAN
    - Growing adoption of advanced HIV screening technologies to drive market
    INDIA
    - Government initiatives such as free HIV testing to drive market
    REST OF ASIA PACIFIC
  • 9.5 LATIN AMERICA
    MACROECONOMIC OUTLOOK FOR LATIN AMERICA
    BRAZIL
    - Increasing uptake of technologically advanced blood screening tests to drive market
    MEXICO
    - Rising establishment of blood banks to support market growth
    REST OF LATIN AMERICA
  • 9.6 MIDDLE EAST & AFRICA
    RISING NUMBER OF HIV DIAGNOSTICS AND SURGICAL PROCEDURES TO FUEL MARKET
    MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
  • 9.7 GCC COUNTRIES
    RISING FOCUS ON HIV TESTING AND IMPROVEMENTS IN HEALTHCARE INFRASTRUCTURE TO SUPPORT MARKET GROWTH
    MACROECONOMIC OUTLOOK FOR GCC COUNTRIES
COMPETITIVE LANDSCAPE
204
  • 10.1 OVERVIEW
  • 10.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
    OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN HIV DIAGNOSTICS MARKET
  • 10.3 REVENUE ANALYSIS, 2021–2023
  • 10.4 MARKET SHARE ANALYSIS, 2023
    RANKING OF KEY MARKET PLAYERS
  • 10.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
    STARS
    EMERGING LEADERS
    PERVASIVE PLAYERS
    PARTICIPANTS
    COMPANY FOOTPRINT: KEY PLAYERS, 2023
    - Company footprint
    - Region footprint
    - Product footprint
    - End-user footprint
  • 10.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
    PROGRESSIVE COMPANIES
    RESPONSIVE COMPANIES
    DYNAMIC COMPANIES
    STARTING BLOCKS
    COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
    - Detailed list of key startups/SME players
    - Competitive benchmarking of key startups/SMEs
  • 10.7 COMPANY VALUATION & FINANCIAL METRICS
  • 10.8 BRAND/PRODUCT COMPARISON
  • 10.9 COMPETITIVE SCENARIO
    PRODUCT/SERVICE LAUNCHES & APPROVALS
    PRODUCT LAUNCHES & APPROVALS
    DEALS
    EXPANSIONS
    OTHER DEVELOPMENTS
COMPANY PROFILES
222
  • 11.1 KEY PLAYERS
    ABBOTT
    - Business overview
    - Products/Services offered
    - Recent developments
    - MnM view
    SIEMENS HEALTHINEERS
    - Business overview
    - Products/Services offered
    - Recent developments
    - MnM view
    GRIFOLS, S.A.
    - Business overview
    - Products/Services offered
    - Recent developments
    - MnM view
    DANAHER CORPORATION
    - Business overview
    - Products/Services offered
    - Recent developments
    - MnM view
    THERMO FISHER SCIENTIFIC INC.
    - Business overview
    - Products/Services offered
    - Recent developments
    - MnM view
    BIO-RAD LABORATORIES, INC.
    - Business overview
    - Products/Services offered
    F. HOFFMANN-LA ROCHE LTD.
    - Business overview
    - Products/Services offered
    - Recent developments
  • 11.2 OTHER PLAYERS
    BIOMÉRIEUX
    HOLOGIC, INC.
    QIAGEN
    BD
    TRINITY BIOTECH
    ORASURE TECHNOLOGIES, INC.
    BIOSYNEX SA
    WONDFO
    GETEIN BIOTECH, INC.
    MERIL LIFE SCIENCES PVT. LTD.
    ACCUBIOTECH CO., LTD.
    BIOLYTICAL LABORATORIES INC.
    BIO LAB DIAGNOSTICS (I) PRIVATE LIMITED
    ALPINE BIOMEDICALS PVT LTD.
    MOLBIO DIAGNOSTICS PVT. LTD.
    FORTRESS DIAGNOSTICS
    ADVACARE PHARMA (ACCUQUIK)
    ADALTIS S.R.L.
APPENDIX
266
  • 12.1 DISCUSSION GUIDE
  • 12.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
  • 12.3 CUSTOMIZATION OPTIONS
  • 12.4 RELATED REPORTS
  • 12.5 AUTHOR DETAILS
LIST OF TABLES
 
  • TABLE 1 HIV DIAGNOSTICS MARKET: INCLUSIONS & EXCLUSIONS
  • TABLE 2 HIV DIAGNOSTICS MARKET: RISK ASSESSMENT ANALYSIS
  • TABLE 3 NUMBER OF PEOPLE LIVING WITH HIV VS. NEW HIV CASES, BY REGION (2023)
  • TABLE 4 AVERAGE SELLING PRICE OF HIV DIAGNOSTICS PRODUCTS, BY KEY PLAYER, 2023
  • TABLE 5 AVERAGE SELLING PRICE TREND, BY TEST TYPE, 2021−2023
  • TABLE 6 AVERAGE SELLING PRICE TREND OF HIV DIAGNOSTIC INSTRUMENTS, BY REGION, 2021−2023 (USD)
  • TABLE 7 HIV DIAGNOSTICS MARKET: ROLE IN ECOSYSTEM
  • TABLE 8 HIV DIAGNOSTICS MARKET: INNOVATIONS & PATENT REGISTRATIONS, 2023–2024
  • TABLE 9 IMPORT DATA FOR HS CODE 9021, BY COUNTRY, 2019–2023 (USD MILLION)
  • TABLE 10 EXPORT DATA FOR HS CODE 9021, BY COUNTRY, 2019–2023 (USD MILLION)
  • TABLE 11 HIV DIAGNOSTICS MARKET: KEY CONFERENCES & EVENTS, 2025–2026
  • TABLE 12 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 13 ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 14 LATIN AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 15 REST OF THE WORLD: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 16 EUROPE: CLASSIFICATION OF DEVICES
  • TABLE 17 JAPAN: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
  • TABLE 18 HIV DIAGNOSTICS MARKET: PORTER’S FIVE FORCES
  • TABLE 19 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY PRODUCT (%)
  • TABLE 20 KEY BUYING CRITERIA FOR PRODUCTS, BY RANK
  • TABLE 21 COMPANY IMPLEMENTATION OF AI IN HIV DIAGNOSTICS MARKET
  • TABLE 22 HIV DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2030 (USD MILLION)
  • TABLE 23 US: HIV DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2030 (MILLION TESTS)
  • TABLE 24 US: HIV DIAGNOSTICS MARKET, BY RAPID TEST TYPE, 2022–2030 (MILLION TESTS)
  • TABLE 25 US: HIV DIAGNOSTICS MARKET, BY CONFIRMATORY TEST TYPE, 2022–2030 (MILLION TESTS)
  • TABLE 26 HIV DIAGNOSTICS MARKET FOR SCREENING TESTS, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 27 SCREENING TESTS MARKET, BY REGION, 2022–2030 (USD MILLION)
  • TABLE 28 NORTH AMERICA: SCREENING TESTS MARKET, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 29 EUROPE: SCREENING TESTS MARKET, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 30 ASIA PACIFIC: SCREENING TESTS MARKET, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 31 LATIN AMERICA: SCREENING TESTS MARKET, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 32 RAPID TESTS MARKET, BY REGION, 2022–2030 (USD MILLION)
  • TABLE 33 NORTH AMERICA: RAPID TESTS MARKET, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 34 EUROPE: RAPID TESTS MARKET, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 35 ASIA PACIFIC: RAPID TESTS MARKET, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 36 LATIN AMERICA: RAPID TESTS MARKET, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 37 ELISA MARKET, BY REGION, 2022–2030 (USD MILLION)
  • TABLE 38 NORTH AMERICA: ELISA MARKET, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 39 EUROPE: ELISA MARKET, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 40 ASIA PACIFIC: ELISA MARKET, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 41 LATIN AMERICA: ELISA MARKET, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 42 OTHER SCREENING TESTS MARKET, BY REGION, 2022–2030 (USD MILLION)
  • TABLE 43 NORTH AMERICA: OTHER SCREENING TESTS MARKET, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 44 EUROPE: OTHER SCREENING TESTS MARKET, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 45 ASIA PACIFIC: OTHER SCREENING TESTS MARKET, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 46 LATIN AMERICA: OTHER SCREENING TESTS MARKET, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 47 CONFIRMATORY TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 48 CONFIRMATORY TESTS MARKET, BY REGION, 2022–2030 (USD MILLION)
  • TABLE 49 NORTH AMERICA: CONFIRMATORY TESTS MARKET, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 50 EUROPE: CONFIRMATORY TESTS MARKET, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 51 ASIA PACIFIC: CONFIRMATORY TESTS MARKET, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 52 LATIN AMERICA: CONFIRMATORY TESTS MARKET, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 53 WESTERN BLOT TESTS MARKET, BY REGION, 2022–2030 (USD MILLION)
  • TABLE 54 NORTH AMERICA: WESTERN BLOT TESTS MARKET, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 55 EUROPE: WESTERN BLOT TESTS MARKET, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 56 ASIA PACIFIC: WESTERN BLOT TESTS MARKET, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 57 LATIN AMERICA: WESTERN BLOT TESTS MARKET, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 58 OTHER CONFIRMATORY TESTS MARKET, BY REGION, 2022–2030 (USD MILLION)
  • TABLE 59 NORTH AMERICA: OTHER CONFIRMATORY TESTS MARKET, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 60 EUROPE: OTHER CONFIRMATORY TESTS MARKET, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 61 ASIA PACIFIC: OTHER CONFIRMATORY TESTS MARKET, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 62 LATIN AMERICA: OTHER CONFIRMATORY TESTS MARKET, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 63 MONITORING TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 64 MONITORING TESTS MARKET, BY REGION, 2022–2030 (USD MILLION)
  • TABLE 65 NORTH AMERICA: MONITORING TESTS MARKET, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 66 EUROPE: MONITORING TESTS MARKET, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 67 ASIA PACIFIC: MONITORING TESTS MARKET, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 68 LATIN AMERICA: MONITORING TESTS MARKET, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 69 VIRAL LOAD TESTS MARKET, BY REGION, 2022–2030 (USD MILLION)
  • TABLE 70 NORTH AMERICA: VIRAL LOAD TESTS MARKET, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 71 EUROPE: VIRAL LOAD TESTS MARKET, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 72 ASIA PACIFIC: VIRAL LOAD TESTS MARKET, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 73 LATIN AMERICA: VIRAL LOAD TESTS MARKET, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 74 CD4 TESTS MARKET, BY REGION, 2022–2030 (USD MILLION)
  • TABLE 75 NORTH AMERICA: CD4 TESTS MARKET, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 76 EUROPE: CD4 TESTS MARKET, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 77 ASIA PACIFIC: CD4 TESTS MARKET, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 78 LATIN AMERICA: CD4 TESTS MARKET, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 79 OTHER HIV DIAGNOSTIC TESTS MARKET, BY REGION, 2022–2030 (USD MILLION)
  • TABLE 80 NORTH AMERICA: OTHER HIV DIAGNOSTIC TESTS MARKET, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 81 EUROPE: OTHER HIV DIAGNOSTIC TESTS MARKET, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 82 ASIA PACIFIC: OTHER HIV DIAGNOSTIC TESTS MARKET, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 83 LATIN AMERICA: OTHER HIV DIAGNOSTIC TESTS MARKET, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 84 HIV DIAGNOSTICS MARKET, BY PRODUCT, 2022–2030 (USD MILLION)
  • TABLE 85 HIV DIAGNOSTICS MARKET FOR CONSUMABLES MARKET, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 86 HIV DIAGNOSTICS MARKET FOR CONSUMABLES, BY REGION, 2022–2030 (USD MILLION)
  • TABLE 87 NORTH AMERICA: HIV DIAGNOSTICS MARKET FOR CONSUMABLES, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 88 EUROPE: HIV DIAGNOSTICS MARKET FOR CONSUMABLES, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 89 ASIA PACIFIC: HIV DIAGNOSTICS MARKET FOR CONSUMABLES, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 90 LATIN AMERICA: HIV DIAGNOSTICS MARKET FOR CONSUMABLES, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 91 ASSAY KITS & REAGENTS OFFERED BY KEY PLAYERS
  • TABLE 92 ASSAY KITS & REAGENTS MARKET, BY REGION, 2022–2030 (USD MILLION)
  • TABLE 93 NORTH AMERICA: ASSAY KITS & REAGENTS MARKET, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 94 EUROPE: ASSAY KITS & REAGENTS MARKET, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 95 ASIA PACIFIC: ASSAY KITS & REAGENTS MARKET, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 96 LATIN AMERICA: ASSAY KITS & REAGENTS MARKET, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 97 OTHER CONSUMABLES MARKET, BY REGION, 2022–2030 (USD MILLION)
  • TABLE 98 NORTH AMERICA: OTHER CONSUMABLES MARKET, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 99 EUROPE: OTHER CONSUMABLES MARKET, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 100 ASIA PACIFIC: OTHER CONSUMABLES MARKET, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 101 LATIN AMERICA: OTHER CONSUMABLES MARKET, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 102 KEY INSTRUMENTS AVAILABLE IN HIV DIAGNOSTICS MARKET
  • TABLE 103 HIV DIAGNOSTICS MARKET FOR INSTRUMENTS, BY REGION, 2022–2030 (USD MILLION)
  • TABLE 104 NORTH AMERICA: HIV DIAGNOSTICS MARKET FOR INSTRUMENTS, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 105 EUROPE: HIV DIAGNOSTICS MARKET FOR INSTRUMENTS, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 106 ASIA PACIFIC: HIV DIAGNOSTICS MARKET FOR INSTRUMENTS, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 107 LATIN AMERICA: HIV DIAGNOSTICS MARKET FOR INSTRUMENTS, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 108 HIV DIAGNOSTICS MARKET FOR SOFTWARE & SERVICES, BY REGION, 2022–2030 (USD MILLION)
  • TABLE 109 NORTH AMERICA: HIV DIAGNOSTICS MARKET FOR SOFTWARE & SERVICES, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 110 EUROPE: HIV DIAGNOSTICS MARKET FOR SOFTWARE & SERVICES, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 111 ASIA PACIFIC: HIV DIAGNOSTICS MARKET FOR SOFTWARE & SERVICES, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 112 LATIN AMERICA: HIV DIAGNOSTICS MARKET FOR SOFTWARE & SERVICES, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 113 HIV DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION)
  • TABLE 114 DIAGNOSTIC LABORATORIES MARKET, BY REGION, 2022–2030 (USD MILLION)
  • TABLE 115 NORTH AMERICA: DIAGNOSTIC LABORATORIES MARKET, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 116 EUROPE: DIAGNOSTIC LABORATORIES MARKET, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 117 ASIA PACIFIC: DIAGNOSTIC LABORATORIES MARKET, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 118 LATIN AMERICA: DIAGNOSTIC LABORATORIES MARKET, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 119 HOSPITALS MARKET, BY REGION, 2022–2030 (USD MILLION)
  • TABLE 120 NORTH AMERICA: HOSPITALS MARKET, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 121 EUROPE: HOSPITALS MARKET, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 122 ASIA PACIFIC: HOSPITALS MARKET, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 123 LATIN AMERICA: HOSPITALS MARKET, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 124 BLOOD BANKS MARKET, BY REGION, 2022–2030 (USD MILLION)
  • TABLE 125 NORTH AMERICA: BLOOD BANKS MARKET, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 126 EUROPE: BLOOD BANKS MARKET, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 127 ASIA PACIFIC: BLOOD BANKS MARKET, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 128 LATIN AMERICA: BLOOD BANKS MARKET, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 129 HOME CARE SETTINGS MARKET, BY REGION, 2022–2030 (USD MILLION)
  • TABLE 130 NORTH AMERICA: HOME CARE SETTINGS MARKET, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 131 EUROPE: HOME CARE SETTINGS MARKET, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 132 ASIA PACIFIC: HOME CARE SETTINGS MARKET, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 133 LATIN AMERICA: HOME CARE SETTINGS MARKET, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 134 OTHER END USERS MARKET, BY REGION, 2022–2030 (USD MILLION)
  • TABLE 135 NORTH AMERICA: OTHER END USERS MARKET, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 136 EUROPE: OTHER END USERS MARKET, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 137 ASIA PACIFIC: OTHER END USERS MARKET, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 138 LATIN AMERICA: OTHER END USERS MARKET, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 139 HIV DIAGNOSTICS MARKET, BY REGION, 2022–2030 (USD MILLION)
  • TABLE 140 NORTH AMERICA: HIV DIAGNOSTICS MARKET, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 141 NORTH AMERICA: HIV DIAGNOSTICS MARKET, BY PRODUCT, 2022–2030 (USD MILLION)
  • TABLE 142 NORTH AMERICA: HIV DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 143 NORTH AMERICA: HIV DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2030 (USD MILLION)
  • TABLE 144 NORTH AMERICA: SCREENING TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 145 NORTH AMERICA: CONFIRMATORY TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 146 NORTH AMERICA: MONITORING TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 147 NORTH AMERICA: HIV DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION)
  • TABLE 148 US: HIV DIAGNOSTICS MARKET, BY PRODUCT, 2022–2030 (USD MILLION)
  • TABLE 149 US: HIV DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 150 US: HIV DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2030 (USD MILLION)
  • TABLE 151 US: SCREENING TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 152 US: CONFIRMATORY TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 153 US: MONITORING TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 154 US: HIV DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION)
  • TABLE 155 CANADA: HIV DIAGNOSTICS MARKET, BY PRODUCT, 2022–2030 (USD MILLION)
  • TABLE 156 CANADA: HIV DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 157 CANADA: HIV DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2030 (USD MILLION)
  • TABLE 158 CANADA: SCREENING TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 159 CANADA: CONFIRMATORY TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 160 CANADA: MONITORING TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 161 CANADA: HIV DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION)
  • TABLE 162 EUROPE: HIV DIAGNOSTICS MARKET, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 163 EUROPE: HIV DIAGNOSTICS MARKET, BY PRODUCT, 2022–2030 (USD MILLION)
  • TABLE 164 EUROPE: HIV DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 165 EUROPE: HIV DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2030 (USD MILLION)
  • TABLE 166 EUROPE: SCREENING TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 167 EUROPE: CONFIRMATORY TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 168 EUROPE: MONITORING TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 169 EUROPE: HIV DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION)
  • TABLE 170 GERMANY: HIV DIAGNOSTICS MARKET, BY PRODUCT, 2022–2030 (USD MILLION)
  • TABLE 171 GERMANY: HIV DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 172 GERMANY: HIV DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2030 (USD MILLION)
  • TABLE 173 GERMANY: SCREENING TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 174 GERMANY: CONFIRMATORY TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 175 GERMANY: MONITORING TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 176 GERMANY: HIV DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION)
  • TABLE 177 UK: HIV DIAGNOSTICS MARKET, BY PRODUCT, 2022–2030 (USD MILLION)
  • TABLE 178 UK: HIV DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 179 UK: HIV DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2030 (USD MILLION)
  • TABLE 180 UK: SCREENING TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 181 UK: CONFIRMATORY TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 182 UK: MONITORING TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 183 UK: HIV DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION)
  • TABLE 184 FRANCE: HIV DIAGNOSTICS MARKET, BY PRODUCT, 2022–2030 (USD MILLION)
  • TABLE 185 FRANCE: HIV DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 186 FRANCE: HIV DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2030 (USD MILLION)
  • TABLE 187 FRANCE: SCREENING TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 188 FRANCE: CONFIRMATORY TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 189 FRANCE: MONITORING TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 190 FRANCE: HIV DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION)
  • TABLE 191 ITALY: HIV DIAGNOSTICS MARKET, BY PRODUCT, 2022–2030 (USD MILLION)
  • TABLE 192 ITALY: HIV DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 193 ITALY: HIV DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2030 (USD MILLION)
  • TABLE 194 ITALY: SCREENING TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 195 ITALY: CONFIRMATORY TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 196 ITALY: MONITORING TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 197 ITALY: HIV DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION)
  • TABLE 198 SPAIN: HIV DIAGNOSTICS MARKET, BY PRODUCT, 2022–2030 (USD MILLION)
  • TABLE 199 SPAIN: HIV DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 200 SPAIN: HIV DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2030 (USD MILLION)
  • TABLE 201 SPAIN: SCREENING TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 202 SPAIN: CONFIRMATORY TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 203 SPAIN: MONITORING TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 204 SPAIN: HIV DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION)
  • TABLE 205 REST OF EUROPE: HIV DIAGNOSTICS MARKET, BY PRODUCT, 2022–2030 (USD MILLION)
  • TABLE 206 REST OF EUROPE: HIV DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 207 REST OF EUROPE: HIV DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2030 (USD MILLION)
  • TABLE 208 REST OF EUROPE: SCREENING TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 209 REST OF EUROPE: CONFIRMATORY TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 210 REST OF EUROPE: MONITORING TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 211 REST OF EUROPE: HIV DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION)
  • TABLE 212 ASIA PACIFIC: HIV DIAGNOSTICS MARKET, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 213 ASIA PACIFIC: HIV DIAGNOSTICS MARKET, BY PRODUCT, 2022–2030 (USD MILLION)
  • TABLE 214 ASIA PACIFIC: HIV DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 215 ASIA PACIFIC: HIV DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2030 (USD MILLION)
  • TABLE 216 ASIA PACIFIC: SCREENING TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 217 ASIA PACIFIC: CONFIRMATORY TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 218 ASIA PACIFIC: MONITORING TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 219 ASIA PACIFIC: HIV DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION)
  • TABLE 220 CHINA: HIV DIAGNOSTICS MARKET, BY PRODUCT, 2022–2030 (USD MILLION)
  • TABLE 221 CHINA: HIV DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 222 CHINA: HIV DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2030 (USD MILLION)
  • TABLE 223 CHINA: SCREENING TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 224 CHINA: CONFIRMATORY TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 225 CHINA: MONITORING TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 226 CHINA: HIV DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION)
  • TABLE 227 JAPAN: HIV DIAGNOSTICS MARKET, BY PRODUCT, 2022–2030 (USD MILLION)
  • TABLE 228 JAPAN: HIV DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 229 JAPAN: HIV DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2030 (USD MILLION)
  • TABLE 230 JAPAN: SCREENING TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 231 JAPAN: CONFIRMATORY TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 232 JAPAN: MONITORING TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 233 JAPAN: HIV DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION)
  • TABLE 234 INDIA: HIV DIAGNOSTICS MARKET, BY PRODUCT, 2022–2030 (USD MILLION)
  • TABLE 235 INDIA: HIV DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 236 INDIA: HIV DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2030 (USD MILLION)
  • TABLE 237 INDIA: SCREENING TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 238 INDIA: CONFIRMATORY TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 239 INDIA: MONITORING TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 240 INDIA: HIV DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION)
  • TABLE 241 REST OF ASIA PACIFIC: HIV DIAGNOSTICS MARKET, BY PRODUCT, 2022–2030 (USD MILLION)
  • TABLE 242 REST OF ASIA PACIFIC: HIV DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 243 REST OF ASIA PACIFIC: HIV DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2030 (USD MILLION)
  • TABLE 244 REST OF ASIA PACIFIC: SCREENING TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 245 REST OF ASIA PACIFIC: CONFIRMATORY TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 246 REST OF ASIA PACIFIC: MONITORING TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 247 REST OF ASIA PACIFIC: HIV DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION)
  • TABLE 248 LATIN AMERICA: HIV DIAGNOSTICS MARKET, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 249 LATIN AMERICA: HIV DIAGNOSTICS MARKET, BY PRODUCT, 2022–2030 (USD MILLION)
  • TABLE 250 LATIN AMERICA: HIV DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE,2022–2030 (USD MILLION)
  • TABLE 251 LATIN AMERICA: HIV DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2030 (USD MILLION)
  • TABLE 252 LATIN AMERICA: SCREENING TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 253 LATIN AMERICA: CONFIRMATORY TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 254 LATIN AMERICA: MONITORING TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 255 LATIN AMERICA: HIV DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION)
  • TABLE 256 BRAZIL: HIV DIAGNOSTICS MARKET, BY PRODUCT, 2022–2030 (USD MILLION)
  • TABLE 257 BRAZIL: HIV DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 258 BRAZIL: HIV DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2030 (USD MILLION)
  • TABLE 259 BRAZIL: SCREENING TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 260 BRAZIL: CONFIRMATORY TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 261 BRAZIL: MONITORING TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 262 BRAZIL HIV DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION)
  • TABLE 263 MEXICO: HIV DIAGNOSTICS MARKET, BY PRODUCT, 2022–2030 (USD MILLION)
  • TABLE 264 MEXICO: HIV DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 265 MEXICO: HIV DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2030 (USD MILLION)
  • TABLE 266 MEXICO: SCREENING TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 267 MEXICO: CONFIRMATORY TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 268 MEXICO: MONITORING TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 269 MEXICO: HIV DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION)
  • TABLE 270 REST OF LATIN AMERICA: HIV DIAGNOSTICS MARKET, BY PRODUCT, 2022–2030 (USD MILLION)
  • TABLE 271 REST OF LATIN AMERICA: HIV DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 272 REST OF LATIN AMERICA: HIV DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2030 (USD MILLION)
  • TABLE 273 REST OF LATIN AMERICA: SCREENING TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 274 REST OF LATIN AMERICA: CONFIRMATORY TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 275 REST OF LATIN AMERICA: MONITORING TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 276 REST OF LATIN AMERICA: HIV DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION)
  • TABLE 277 MIDDLE EAST & AFRICA: HIV DIAGNOSTICS MARKET, BY PRODUCT, 2022–2030 (USD MILLION)
  • TABLE 278 MIDDLE EAST & AFRICA: HIV DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 279 MIDDLE EAST & AFRICA: HIV DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2030 (USD MILLION)
  • TABLE 280 MIDDLE EAST & AFRICA: SCREENING TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 281 MIDDLE EAST & AFRICA: CONFIRMATORY TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 282 MIDDLE EAST & AFRICA: MONITORING TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 283 MIDDLE EAST & AFRICA: HIV DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION)
  • TABLE 284 MIDDLE EAST & AFRICA: MACROECONOMIC INDICATORS
  • TABLE 285 GCC COUNTRIES: HIV DIAGNOSTICS MARKET, BY PRODUCT, 2022–2030 (USD MILLION)
  • TABLE 286 GCC COUNTRIES: HIV DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 287 GCC COUNTRIES: HIV DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2030 (USD MILLION)
  • TABLE 288 GCC COUNTRIES: SCREENING TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 289 GCC COUNTRIES: CONFIRMATORY TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 290 GCC COUNTRIES: MONITORING TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 291 GCC COUNTRIES: HIV DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION)
  • TABLE 292 GCC COUNTRIES: MACROECONOMIC INDICATORS
  • TABLE 293 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS INHIV DIAGNOSTICS MARKET
  • TABLE 294 HIV DIAGNOSTICS MARKET: DEGREE OF COMPETITION
  • TABLE 295 HIV DIAGNOSTICS MARKET: REGION FOOTPRINT
  • TABLE 296 HIV DIAGNOSTICS MARKET: PRODUCT FOOTPRINT
  • TABLE 297 HIV DIAGNOSTICS MARKET: END-USER FOOTPRINT
  • TABLE 298 HIV DIAGNOSTICS MARKET: DETAILED LIST OF KEY STARTUPS/SME PLAYERS
  • TABLE 299 HIV DIAGNOSTICS MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES
  • TABLE 300 HIV DIAGNOSTICS MARKET: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021–MARCH 2025
  • TABLE 301 HIV DIAGNOSTICS MARKET: DEALS, JANUARY 2021–MARCH 2025
  • TABLE 302 HIV DIAGNOSTICS MARKET: EXPANSIONS, JANUARY 2021–MARCH 2025
  • TABLE 303 HIV DIAGNOSTICS MARKET: OTHER DEVELOPMENTS, JANUARY 2021–MARCH 2025
  • TABLE 304 ABBOTT: COMPANY OVERVIEW
  • TABLE 305 ABBOTT: PRODUCTS/SERVICES OFFERED
  • TABLE 306 ABBOTT: DEALS, JANUARY 2021–JANUARY 2025
  • TABLE 307 SIEMENS HEALTHINEERS: COMPANY OVERVIEW
  • TABLE 308 GRIFOLS, S.A.: COMPANY OVERVIEW
  • TABLE 309 GRIFOLS, S.A.: PRODUCTS/SERVICES OFFERED
  • TABLE 310 GRIFOLS, S.A.: DEALS, JANUARY 2021– JANUARY 2025
  • TABLE 311 DANAHER: COMPANY OVERVIEW
  • TABLE 312 DANAHER: PRODUCTS/SERVICES OFFERED
  • TABLE 313 DANAHER: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021–JANUARY 2025
  • TABLE 314 DANAHER: DEALS, JANUARY 2021–JANUARY 2025
  • TABLE 315 DANAHER: EXPANSIONS, JANUARY 2021–JANUARY 2025
  • TABLE 316 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW
  • TABLE 317 THERMO FISHER SCIENTIFIC INC.: PRODUCTS/SERVICES OFFERED
  • TABLE 318 THERMO FISHER SCIENTIFIC INC.: PRODUCT/SERVICE LAUNCHES & APPROVALS, JANUARY 2021–JANUARY 2025
  • TABLE 319 THERMO FISHER SCIENTIFIC INC.: DEALS, JANUARY 2021−JANUARY 2025
  • TABLE 320 BIO-RAD LABORATORIES, INC.: COMPANY OVERVIEW
  • TABLE 321 BIO-RAD LABORATORIES, INC.: PRODUCTS/SERVICES OFFERED
  • TABLE 322 BIO-RAD LABORATORIES, INC.: DEALS, JANUARY 2021– JANUARY 2025
  • TABLE 323 F. HOFFMANN-LA ROCHE LTD..: COMPANY OVERVIEW
  • TABLE 324 F. HOFFMANN-LA ROCHE LTD..: PRODUCTS/SERVICES OFFERED
  • TABLE 325 F. HOFFMANN-LA ROCHE LTD.: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021–JANUARY 2025
  • TABLE 326 F. HOFFMANN-LA ROCHE LTD..: DEALS, JANUARY 2021– JANUARY 2025
  • TABLE 327 F. HOFFMANN-LA ROCHE LTD..: EXPANSIONS, JANUARY 2021– JANUARY 2025
  • TABLE 328 BD: COMPANY OVERVIEW
  • TABLE 329 TRINITY BIOTECH: COMPANY OVERVIEW
  • TABLE 330 BIOSYNEX SA: COMPANY OVERVIEW
  • TABLE 331 GETEIN BIOTECH, INC.: COMPANY OVERVIEW
  • TABLE 332 ADALTIS S.R.L.: COMPANY OVERVIEW
LIST OF FIGURES
 
  • FIGURE 1 MARKETS & REGIONS COVERED
  • FIGURE 2 HIV DIAGNOSTICS MARKET: RESEARCH DESIGN
  • FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
  • FIGURE 4 BOTTOM-UP APPROACH: COMPANY REVENUE ESTIMATION APPROACH
  • FIGURE 5 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
  • FIGURE 6 HIV DIAGNOSTICS MARKET: TOP-DOWN APPROACH
  • FIGURE 7 DATA TRIANGULATION METHODOLOGY
  • FIGURE 8 HIV DIAGNOSTICS MARKET: STUDY ASSUMPTIONS
  • FIGURE 9 HIV DIAGNOSTICS MARKET, BY PRODUCT, 2025 VS. 2030 (USD MILLION)
  • FIGURE 10 HIV DIAGNOSTICS MARKET, BY TEST TYPE, 2025 VS. 2030 (USD MILLION)
  • FIGURE 11 HIV DIAGNOSTICS MARKET, BY END USER, 2025 VS. 2030 (USD MILLION)
  • FIGURE 12 HIV DIAGNOSTICS MARKET, BY REGION, 2025 VS. 2030 (USD MILLION)
  • FIGURE 13 INCREASING PREVALENCE OF HIV AND RISING BLOOD DONATIONS TO PROPEL MARKET
  • FIGURE 14 HIV DIAGNOSTICS MARKET, BY PRODUCT, 2025 VS. 2030 (USD MILLION)
  • FIGURE 15 HIV DIAGNOSTICS MARKET, BY TEST TYPE, 2025 VS. 2030 (USD MILLION)
  • FIGURE 16 HIV DIAGNOSTICS SCREENING TESTS MARKET, BY TYPE, 2025 VS. 2030 (USD MILLION)
  • FIGURE 17 HIV DIAGNOSTICS CONFIRMATORY TESTS MARKET, BY TYPE, 2025 VS. 2030 (USD MILLION)
  • FIGURE 18 HIV DIAGNOSTICS MONITORING TESTS MARKET, BY TYPE, 2025 VS. 2030 (USD MILLION)
  • FIGURE 19 HIV DIAGNOSTICS MARKET, BY END USER, 2025 VS. 2030 (USD MILLION)
  • FIGURE 20 ASIA PACIFIC REGION TO GROW AT HIGHEST CAGR DURING FORECAST PERIOD
  • FIGURE 21 HIV DIAGNOSTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
  • FIGURE 22 NEW REVENUE POCKETS FOR PLAYERS IN HIV DIAGNOSTICS MARKET
  • FIGURE 23 HIV DIAGNOSTICS MARKET: VALUE CHAIN ANALYSIS
  • FIGURE 24 HIV DIAGNOSTICS MARKET: SUPPLY CHAIN ANALYSIS
  • FIGURE 25 HIV DIAGNOSTICS MARKET: ECOSYSTEM ANALYSIS
  • FIGURE 26 INVESTMENT & FUNDING SCENARIO, 2018–2025
  • FIGURE 27 HIV DIAGNOSTICS MARKET: PATENT ANALYSIS, JANUARY 2014–DECEMBER 2024
  • FIGURE 28 HIV DIAGNOSTICS MARKET: PORTER’S FIVE FORCES ANALYSIS
  • FIGURE 29 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY PRODUCT
  • FIGURE 30 KEY BUYING CRITERIA, BY PRODUCT
  • FIGURE 31 MARKET POTENTIAL OF AI IN HIV DIAGNOSTICS
  • FIGURE 32 HIV DIAGNOSTICS MARKET SEGMENTATION, BY PRODUCT
  • FIGURE 33 NORTH AMERICA: HIV DIAGNOSTICS MARKET SNAPSHOT
  • FIGURE 34 ASIA PACIFIC: HIV DIAGNOSTICS MARKET SNAPSHOT
  • FIGURE 35 REVENUE ANALYSIS OF KEY PLAYERS IN HIV DIAGNOSTICS MARKET, 2021−2023 (USD MILLION)
  • FIGURE 36 MARKET SHARE ANALYSIS OF KEY PLAYERS IN HIV DIAGNOSTICS MARKET (2023)
  • FIGURE 37 RANKING OF KEY PLAYERS IN HIV DIAGNOSTICS MARKET, 2023
  • FIGURE 38 HIV DIAGNOSTICS MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2023
  • FIGURE 39 HIV DIAGNOSTICS MARKET: COMPANY FOOTPRINT
  • FIGURE 40 HIV DIAGNOSTICS MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2023
  • FIGURE 41 EV/EBITDA OF KEY VENDORS
  • FIGURE 42 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS
  • FIGURE 43 HIV DIAGNOSTICS MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS
  • FIGURE 44 ABBOTT: COMPANY SNAPSHOT (2023)
  • FIGURE 45 SIEMENS HEALTHINEERS: COMPANY SNAPSHOT (2023)
  • FIGURE 46 GRIFOLS, S.A.: COMPANY SNAPSHOT (2023)
  • FIGURE 47 DANAHER: COMPANY SNAPSHOT (2023)
  • FIGURE 48 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2023)
  • FIGURE 49 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2023)
  • FIGURE 50 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2023)

 

This study involved four major activities in estimating the current size of the HIV diagnostics market. Exhaustive secondary research was carried out to collect information on the market, its peer markets, and its parent market. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. After that, market breakdown and data triangulation procedures were used to estimate segments and subsegments' market size.

Secondary Research

In the secondary research process, various secondary sources such as annual reports, press releases & investor presentations of companies, white papers, certified publications, articles by recognized authors, gold-standard & silver-standard websites, regulatory bodies, and databases (such as D&B Hoovers, Bloomberg Business, and Factiva) were referred to identify and collect information for this study.

Primary Research

In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. Primary sources were mainly industry experts from the core and related industries and preferred suppliers, manufacturers, distributors, service providers, technology developers, researchers, and organizations related to all segments of this industry’s value chain. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts, C-level executives of key market players, and industry consultants, to obtain and verify the critical qualitative and quantitative information as well as assess prospects.

The following is a breakdown of the primary respondents:

HIV Diagnostics Market

Note 1: Others include sales managers, marketing managers, and product managers.

Note 2: Companies are classified into tiers based on their total revenues. As of 2022/2023, Tier 1 = >USD 100 million, Tier 2 = USD 10 million to USD 100 million, and Tier 3 = < USD 10 million.

To know about the assumptions considered for the study, download the pdf brochure

COMPANY NAME DESIGNATION
Abbott (US) General Manager
Siemens Healthineers AG (Germany) Area Sales Manager

Market Size Estimation

Both top-down and bottom-up approaches were used to estimate and validate the HIV diagnostics market's total size. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

  • The key players in the industry have been identified through extensive secondary research
  • The revenues generated by leading players operating in the HIV diagnostics market have been determined through primary and secondary research
  • All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources

The research methodology used to estimate the market size includes the following:

HIV Diagnostics Market

Data Triangulation

After arriving at the overall market size applying the process mentioned above, the total market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.

Market Definition

HIV diagnostic tests are used to detect the presence of human immunodeficiency virus in human serum. This report covers various tests used for the detection of the virus. HIV diagnostics can categorized into different techniques and products (including kits, assays, tests, reagents, and analyzers) used by healthcare professionals to detect HIV.

Stakeholders

  • Senior Management
  • End User
  • Finance/Procurement Department 
  • R&D Department

Report Objectives

  • To define, describe, segment, and forecast the global HIV diagnostics market by product, test type, end user, and region
  • To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
  • To analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall HIV diagnostics market
  • To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
  • To forecast the size of the market segments with respect to five regions, namely, North America, Europe, the Asia Pacific, Latin America, the Middle East & Africa and GCC.
  • To profile the key players and comprehensively analyze their product portfolios, market positions, and core competencies
  • To track and analyze company developments such as product launches, agreements, partnerships, and acquisitions in the HIV diagnostics market
  • To benchmark players within the market using the proprietary "Competitive Leadership Mapping" framework, which analyzes market players on various parameters within the broad categories of business and product strategy

Previous Versions of this Report

HIV Diagnosis Market by Test Type (Antibody (ELISA, Rapid, Western Blot), Viral Load, CD4 Count, Early Infant, Viral Identification, Product (Assay, Kit, Reagent, Instrument, Software, Services), End User (Hospitals) - Global Forecast to 2021

Report Code MD 5067
Published in Mar, 2017, By MarketsandMarkets™

Custom Market Research Services

We Will Customise The Research For You, In Case The Report Listed Above Does Not Meet With Your Requirements

Get 10% Free Customisation

Growth opportunities and latent adjacency in HIV Diagnostics Market

DMCA.com Protection Status